Delving into the Latest Updates on Sanofi-Aventis Ltd. with Synapse

Overview

Basic Info

Introduction

Sanofi-Aventis Ltd. aspires to be at the forefront of the immunology sector, striving to improve the lives of millions affected by various immune-mediated conditions, including dermatological, respiratory, and gastroenterological diseases. The company is dedicated to revolutionizing medical practice with cutting-edge science, benefiting both its employees and the broader communities it impacts.

Tags

Neoplasms

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

ER(Estrogen receptors)	1

Even though in Russia there has been a growing interest in conducting non-interventional studies (NIS) in recent years, the existence of gaps in their legal regulation leads to the fact that many medical institutions and healthcare professionals refuse to participate in this type of activities. This paper analyzes such refusals and discusses several legal aspects, such as the contracting with medical organizations and investigators, issues of personal data protection, as well as a brief comparative analysis of the requirements for non-intervention trials in the EEU countries. To overcome the organizational barriers of NIS, it is necessary to develop common criteria/concepts at both pharmaceutical companies and professional medical communities levels, with the subsequent training of healthcare professionals and organizers on various aspects of NIS. This article will be helpful for all healthcare professionals, especially physicians, researchers and decision-makers, who decide to conduct NIS at medical institutions.

Acta Poloniae Pharmaceutica

Mechanistic models in the assessment of drotaverine hydrochloride solubility after tablet disintegration in the presence of selected excipients in pharmacopoeial acceptor fluid

Author: Ga, Grzegorz Do£ ; Marczy-Ski, Zbigniew ; Zgoda, Marian M.

Research studies have been carried out on the possibility of producing a solid dosage form with drotaverine hydrochloride by direct compression technique with the use of individual excipients such as: Vivapur, Prosolv 90 HD, Emdex, Emcompress, lactose and Pearlitol 200 SD.Granulometric parameters of tablet mass, model dosage forms as well as a reference form were analyzed.The determined pharmaceutical availability in the form of a Q% coefficient was in the time function (t, min) an inspiration for estimating the rate of dissolution of the therapeutic agent in the presence of an excipient and for assessing the impact of the grain structure and surface in the environment of 0.1 M of HCl on the process of its sorption.Kinetic equations of "0" and "I" order and Higuchi, Korsmeyer-Peppas and Hixson-Crowell models, based on the thesis that the process of dissolution (release) is consistent with Ficks law, were used to describe the process of dissolution of drotaverine hydrochloride in 0.1 M HCl.It results from the anal. of approximation equations, both in the kinetic and mechanistic model (Higuchi, Korsmeyer-Peppas, Hixson-Crowell models), that sym. to the dissolution process there comes to adsorption of the therapeutic agent by granulometric grains which points to its deficit in the acceptor fluid (Freundlich adsorption isotherm).Formulation with Prosolv 90HD is characterized by a profile of the rate of dissolution of drotaverine hydrochloride that is compatible with a reference form.

100 Deals associated with Sanofi-Aventis Ltd.

Login to view more data

100 Translational Medicine associated with Sanofi-Aventis Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

1

7

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

RU-58668 ( ER )	Neoplasms More	Preclinical
Rimonabant ( CB1R )	Overweight More	Withdrawn
SSR-162329 ( DPP-4 )	Diabetes Mellitus, Type 2 More	Discontinued
FK-779	Multiple Sclerosis More	Discontinued
HMR-3787 ( 50S subunit )	Bacterial Infections More	Discontinued